Phosphodiesterase 4 inhibitors

US7495017B2 · kind B2 · utility

Assignee

• Memory Pharmaceuticals Corporation · US

Inventors

• Allen Hopper · Glen Rock, US
• Erik Kuester · Rochester, US
• Robert F. Dunn · Towaco, US
• Richard Conticello · Ossining, US

Key dates

• Filing date: May 1, 2007
• Grant date: Feb 24, 2009
• Expiry date: May 1, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.